HOME >> BIOLOGY >> NEWS
Anti-cholesterol drug treats Alzheimer's disease in mice

ficant cognitive benefit for AD patients with normal serum cholesterol."

Although CP-113,818 has not been tested in clinical trials, another ACAT inhibitor, avasimibe, developed by Pfizer, is now in final clinical trials as a treatment for vascular disease and atherosclerosis. That drug is "considered safe for human use, with a good therapeutic window," wrote Kovacs and her colleagues.

"Our results suggest that slow-release biopolymer administration of ACAT inhibitors may be considered as a potential strategy for the treatment and prevention of Alzheimer's disease, alone or in combination with statins," they wrote.

Birgit Hutter-Paier, Henri J. Huttunen, Luigi Puglielli, Christopher B. Eckman, Doo Yeon Kim, Alexander Hofmeister, Robert D. Moir, Sarah B. Domnitz, Matthew P. Frosch, Manfred Windisch, and Dora M. Kovacs: "The ACAT Inhibitor CP-113,818 Markedly Reduces Amyloid Pathology in a Mouse Model of Alzheimer's Disease"


'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
13-Oct-2004


Page: 1 2

Related biology news :

1. Stem cell procedure successfully treats amyloidosis patients
2. New compound effectively treats fungal infections
3. Antibiotic treats lymphoma of the eye
4. Gene therapy advance treats hemophilia in mouse models
5. Device creates electricity and treats wastewater
6. Antarctic ice shelf retreats happened before
7. Gilbert Foundation and American Fed for Aging Research award grants on Alzheimers disease
8. Link identified between Alzheimers disease and glaucoma
9. UCF research links proteins, stem cells and potential Alzheimers treatment
10. Journal of Alzheimers Disease achieves significant impact factor
11. Alzheimers prevention role discovered for prions

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 27, 2016  Sequenom, Inc. (NASDAQ: SQNM ... lives through the development of innovative products and services, ... the United States denied its petition to ... of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are ... by the Supreme Court,s Mayo Collaborative Services v. Prometheus ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and ... clinical trial team. , Using the CONSULT module, patients and physicians can schedule a ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
Breaking Biology Technology:
Cached News: